# Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

> **NCT02180711** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 113 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** acalabrutinib
- **DRUG:** rituximab (IV)
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02180711
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-12-29
- **Primary completion:** 2023-08-25
- **Final completion:** 2028-12-29
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2025-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02180711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02180711, "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02180711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*